IDD001 MAb exhibited the highest Complement Dependent Cytotoxicity (CDC) efficiency on B-ALL sample
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
From its proprietary MAb library, iDD biotech has generated:
· next-generation, humanized, Fc optimized and afucosylated anti CD19 MAb,
· with higher level of apoptosis compared with MAbs anti CD19 under development,
· with enhanced binding of FcRIIIa and ADCC (patent WO/2012/010561/01056),
· against a broad range of B-lymphoma and leukaemia cell lines,
· with or without complement binding ability (MAb IDD001 versus MAb IDD002),
· produced using generic wild type CHO cell lines.
(Poster, iDD biotech, View Source [SID:1234502457])